News & Updates
Filter by Specialty:
Ebdarokimab works wonders for patients with plaque psoriasis
14 Oct 2024
byStephen Padilla
A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.
Ebdarokimab works wonders for patients with plaque psoriasis
14 Oct 2024
MARIPOSA update: Amivantamab-lazertinib bests osimertinib for EGFRm NSCLC at 3 years
14 Oct 2024
byAudrey Abella
The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).
